Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms

Figure 9 Kaplan-Meier survival curves for overall survival stratified by biomarker levels and subtype in patients with lymphoproliferative neoplasms (n = 90). Panels show programmed death-ligand 1 (PD-L1)/C-X-C motif chemokine receptor 3 (CXCR3) (low vs high) for diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), and the systemic inflammation response index (SIRI; high vs low) for DLBCL and CLL. Dark blue indicates the group with longer overall survival (low PD-L1/CXCR3 in both subtypes, high SIRI in CLL), and dark red indicates the contrast group (high PD-L1/CXCR3, low SIRI in CLL, and high SIRI in DLBCL, where non-significant). P-values are from log-rank tests, with risk tables below each curve. Mean overall survival values are 285 ± 1.5 months for low PD-L1/CXCR3 in DLBCL, 30.0 ± 1.0 months in CLL, 20.0 ± 2.0 months for high SIRI in DLBCL, and 25.0 ± 1.5 months in CLL. DLBCL: Diffuse large B-cell lymphoma; PD-L1: Programmed death-ligand 1; CXCR3: C-X-C motif chemokine receptor 3; CCL: Chronic lymphocytic leukemia; SIRI: Systemic inflammation response index.